Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2013)
Fate Therapeutics' (FATE) quarterly Gains from Investment Securities came in at $29000.0 in Q4 2013, up 1550.0% YoY from $1757.6 in Q4 2012, and up 193.55% on a QoQ basis from -$31000.0 in Q3 2013.
Powered by 
Analysis
Fate Therapeutics (FATE) Gains from Investment Securities (2012 - 2013) Analysis & Trends
Fate Therapeutics (FATE) has 2 years of Gains from Investment Securities data on file, last reported at $29000.0 in Q4 2013.
- Quarterly Gains from Investment Securities rose 1550.0% year-over-year to $29000.0 in Q4 2013, while the trailing twelve-month figure through Dec 2017 was $20000.0 (changed N/A YoY) and the FY2017 annual result came in at $30000.0, changed N/A from the prior year.
- Gains from Investment Securities grew to $29000.0 in Q4 2013, from -$31000.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $29000.0 in Q4 2013 to a low of -$31000.0 in Q3 2013.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Fate Therapeutics | 299.79 Mn | 299.79 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2013 | 29,000.00 |
| Sep 30, 2013 | -31,000.00 |
| Jun 30, 2013 | 22,000.00 |
| Mar 31, 2013 | -12,000.00 |
| Dec 31, 2012 | -2,000.00 |